Pyxis Oncology, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Pyxis Oncology, Inc. (PYXS) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 32.32 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-13
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 32.32M shares, a 2292.51% increase year-over-year.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 29.57M shares, a 2395.13% increase year-over-year.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 1.58M shares, a 45.34% increase year-over-year.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 1.35M shares.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 8.49M shares, a 724.14% increase from fiscal 2020.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 1.03M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 32.32M shares 10-Q · filed 2022-05-13 | 30.94M shares derived: average of 2 quarters · filed 2022-05-13 | 21.16M shares derived: average of 3 quarters · filed 2022-05-13 | |
| 2021-12-31 | 29.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 15.57M shares derived: average of 2 quarters · filed 2022-03-29 | 8.49M shares 10-K · filed 2022-03-29 | |
| 2021-09-30 | 1.58M shares 10-Q · filed 2021-11-15 | 1.47M shares 10-Q · filed 2021-11-15 | ||
| 2021-03-31 | 1.35M shares 10-Q · filed 2022-05-13 | 1.27M shares derived: average of 2 quarters · filed 2022-05-13 | 1.21M shares derived: average of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | 1.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 1.14M shares derived: average of 2 quarters · filed 2022-03-29 | 1.03M shares 10-K · filed 2022-03-29 | |
| 2020-09-30 | 1.09M shares 10-Q · filed 2021-11-15 | 979.08K shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |